Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

832 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A pharmacodynamic comparison of a personalized strategy for anti-platelet therapy versus ticagrelor in achieving a therapeutic window.
Malhotra N, Abunassar J, Wells GA, McPherson R, Fu A, Hibbert B, Labinaz M, Le May M, Dick A, Glover C, Froeschl M, Marquis JF, Tran L, Bernick J, Chong AY, So DY; CArdiovascular Percutaneous Intervention TriAL (CAPITAL) investigators. Malhotra N, et al. Int J Cardiol. 2015 Oct 15;197:318-25. doi: 10.1016/j.ijcard.2015.06.016. Epub 2015 Jun 15. Int J Cardiol. 2015. PMID: 26151596
A pharmacodynamic analysis for the co-administration of inducers of CYP3A with ticagrelor: A cautionary tale in managing patients with acute coronary syndromes.
Pourdjabbar A, Hibbert B, Chong AY, Abunassar J, Malhotra N, Whitten TA, Le May MR, So DY; CAPITAL investigators. Pourdjabbar A, et al. Among authors: malhotra n. Int J Cardiol. 2016 Jul 1;214:423-5. doi: 10.1016/j.ijcard.2016.03.153. Epub 2016 Mar 24. Int J Cardiol. 2016. PMID: 27088404 No abstract available.
Ischemic and bleeding outcomes after coronary artery bypass grafting among patients initially treated with a P2Y12 receptor antagonist for acute coronary syndromes: Insights on timing of discontinuation of ticagrelor and clopidogrel prior to surgery.
Russo JJ, James TE, Ruel M, Dupuis JY, Singh K, Goubran D, Malhotra N, Rubens F, Chong AY, Hibbert B, Boland P, Tran DT, Tanguay JF, Lordkipanidzé M, Perrault L, Wells GA, Bourke M, Chan V, So DY. Russo JJ, et al. Among authors: malhotra n. Eur Heart J Acute Cardiovasc Care. 2019 Sep;8(6):543-553. doi: 10.1177/2048872617740832. Epub 2018 Jan 9. Eur Heart J Acute Cardiovasc Care. 2019. PMID: 29313713
No sex-based difference in cardiogenic shock: A post-hoc analysis of the DOREMI trial.
Prosperi-Porta G, Motazedian P, Di Santo P, Jung RG, Parlow S, Abdel-Razek O, Simard T, Hutson J, Malhotra N, Fu A, Ramirez FD, Froeschl M, Mathew R, Hibbert B; CAPITAL DOREMI investigators. Prosperi-Porta G, et al. Among authors: malhotra n. J Cardiol. 2022 Oct;80(4):358-364. doi: 10.1016/j.jjcc.2022.06.001. Epub 2022 Jun 17. J Cardiol. 2022. PMID: 35725945 Free article. Clinical Trial.
Arrhythmic Events and Mortality in Patients With Cardiogenic Shock on Inotropic Support: Results of the DOREMI Randomized Trial.
Jung RG, Di Santo P, Mathew R, Simard T, Parlow S, Weng W, Abdel-Razek O, Malhotra N, Cheung M, Hutson JH, Marbach JA, Motazedian P, Thibert MJ, Fernando SM, Nery PB, Nair GM, Russo JJ, Hibbert B, Ramirez FD. Jung RG, et al. Among authors: malhotra n. Can J Cardiol. 2023 Apr;39(4):394-402. doi: 10.1016/j.cjca.2022.09.013. Epub 2022 Sep 20. Can J Cardiol. 2023. PMID: 36150583 Clinical Trial.
832 results